Form 8-K - Current report:
SEC Accession No. 0001193125-25-001787
Filing Date
2025-01-06
Accepted
2025-01-06 06:06:00
Documents
14
Period of Report
2025-01-03
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d909904d8k.htm   iXBRL 8-K 41792
2 EX-3.1 d909904dex31.htm EX-3.1 5252
  Complete submission text file 0001193125-25-001787.txt   180209

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20250103.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20250103_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20250103_pre.xml EX-101.PRE 12158
16 EXTRACTED XBRL INSTANCE DOCUMENT d909904d8k_htm.xml XML 3975
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 25508942
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)